YolTech Therapeutics Raises $45M in Series B to Advance In Vivo Gene Editing Pipeline Toward Phase 3
YolTech Therapeutics has raised $45M in Series B funding to advance its in vivo CRISPR therapies. Lead candidate YOLT-101, for familial hypercholesterolemia, shows strong LDL-C reduction in early trials, with a Phase 3 study on the horizon—a milestone for Chinese gene editing.
Chinese biotech company YolTech Therapeutics announced today the successful completion of its Series B financing round, raising over RMB 300 million (~$45 million). The round was led by the AstraZeneca-CICC Healthcare Industrial Fund, with participation from Sungent BioVenture, TC Capital, Innochip Capital, and continued support from K2 Venture Partners, Far East Horizon, and Destone Capital. This brings the company’s total funding to over RMB 575 million (~$80M).
Founded in Shanghai, YolTech is a clinical-stage biotechnology company focused on in vivo gene editing therapies using mRNA-LNP delivery systems. All four of its product candidates are now in clinical stages—making it one of the global leaders in this cutting-edge field.
Four Programs, One Platform
YolTech is building its pipeline around in vivo CRISPR-based therapies, aiming for single-dose, curative treatments for severe genetic diseases. Each candidate uses proprietary gene editing tools and next-generation LNPs to deliver the system directly to liver cells.
- YOLT-101 is an adenine base editing therapy for familial hypercholesterolemia (FH). Early data from a Chinese IIT study (NCT06458010) showed that a single injection significantly lowered LDL-C levels in patients, with favorable safety and durability. The therapy uses YolTech’s own YolBE hpABE5 editor and LNPs. Salubris Pharmaceuticals holds China rights.
- YOLT-201 targets transthyretin amyloidosis (ATTR-CM). In early clinical testing, serum TTR levels dropped by ~90% after a single dose, with sustained effects and good tolerability — suggesting potential for functional cure.
- YOLT-203 is designed for primary hyperoxaluria type 1 (PH1). It uses a Cas12-based system (YolCas12HF) to edit the HAO1 gene and reduce oxalate production at the source — a promising approach for one-time curative therapy.
- YOLT-202 aims to treat alpha-1 antitrypsin deficiency (AATD) via precise repair of the SERPINA1 PiZ mutation, using YolTech’s evolved adenine base editor (YolBE). Preclinical data suggests high editing precision with minimal off-target effects or bystander edits.
Why This Matters
YolTech’s rapid clinical progress, combined with its in-house development of gene editing tools and delivery systems, positions it as a standout player in China’s emerging gene editing field. It’s also a sign that China's biotech sector is shifting from fast-follow to front-runner, particularly in high-bar innovation areas like genome editing.
This Series B funding will support continued clinical development and preparation for YolTech’s first Phase 3 trial — a milestone that could make it the first Chinese in vivo gene editing company to reach that stage.
As global investors continue looking for differentiated gene therapy assets, YolTech is one to watch — not just for its pipeline, but for what it represents: the rise of globally competitive innovation coming from China in some of biotech’s most advanced therapeutic areas.
For More Details: https://www.yoltx.com